Chrisoulidou A, Beshyah S A, Rutherford O, Spinks T J, Mayet J, Kyd P, Anyaoku V, Haida A, Ariff B, Murphy M, Thomas E, Robinson S, Foale R, Johnston D G
Department of Clinical Physics, Imperial College School of Medicine, St. Mary's Hospital, London, United Kingdom.
J Clin Endocrinol Metab. 2000 Oct;85(10):3762-9. doi: 10.1210/jcem.85.10.6910.
Short-term studies of GH replacement in adult hypopituitarism have usually demonstrated beneficial effects on body composition and circulating lipids, with neutral or occasionally adverse effects on glucose tolerance. Fasting hyperinsulinemia has been reported. GH effects on cardiac function have been variable. The effects of long-term GH therapy, taking into account the consequences of increasing age, are not fully known. Thirty-three hypopituitary, initially middle-aged adults were studied over a 7-yr period; 12 patients took GH therapy (mean, 0.7 mg daily) continuously (group A); 11 took GH for only 6-18 months, a minimum of 5 yr previously (group B); and 10 patients never received GH therapy (group C). Other pituitary replacement was maintained. Effects on anthropometry, body composition (by bioimpedance analysis, total body potassium, and dual energy x-ray absorptiometry), circulating lipids, glucose and insulin concentrations, cardiac 2-dimensional and Doppler echocardiography, and exercise tolerance were assessed before and after the treatment period. Continuous GH therapy had no significant effect on body weight, but it prevented the increase in waist circumference and waist to hip ratio that occurred in the patients without GH substitution (waist to hip ratio, group A, 0.87+/-0.08 at baseline, 0.85+/-0.09 at 7 yr; group B, 0.89+/-0.11 at baseline, 0.94+/-0.11 at 7 yr; P < 0.005 for GH effect; group C, 0.87+/-0.10 at baseline, 0.92+/-0.10 at 7 yr; P < 0.005 for GH effect). A GH-induced decrease in subscapular skinfold thickness was also observed. By bioimpedance analysis, GH therapy caused an increase in total body water and fat-free mass, and a decrease in the percent body fat. Although changes occurred with time in all groups, no significant additional GH therapy effects were observed on glucose tolerance, insulin concentrations, lipid levels, cardiac dimensions, echocardiographic diastolic function, or exercise tolerance. In conclusion, prolonged GH substitution in middle-aged hypopituitary adults causes a sustained improvement in body composition. Other benefits, e.g. on lipid levels and exercise tolerance, were not apparent at 7 yr when comparisons were made with GH-untreated hypopituitary controls. Potentially adverse effects on glucose tolerance and insulinemia did not develop with prolonged GH therapy.
对成年垂体功能减退患者进行生长激素(GH)替代治疗的短期研究通常表明,其对身体成分和循环脂质有益,对葡萄糖耐量则有中性或偶尔的不利影响。有报道称存在空腹高胰岛素血症。GH对心脏功能的影响存在差异。考虑到年龄增长的影响,长期GH治疗的效果尚不完全清楚。在7年期间对33名最初为中年的垂体功能减退患者进行了研究;12名患者持续接受GH治疗(平均每日0.7毫克)(A组);11名患者仅在至少5年前接受了6 - 18个月的GH治疗(B组);10名患者从未接受过GH治疗(C组)。维持其他垂体激素替代治疗。在治疗前后评估了对人体测量学、身体成分(通过生物电阻抗分析、全身钾含量和双能X线吸收法)、循环脂质、血糖和胰岛素浓度、心脏二维和多普勒超声心动图以及运动耐量的影响。持续GH治疗对体重无显著影响,但可防止未接受GH替代治疗的患者腰围和腰臀比增加(腰臀比,A组,基线时为0.87±0.08,7年时为0.85±0.09;B组,基线时为0.89±0.11,7年时为0.94±0.11;GH治疗效果P<0.005;C组,基线时为0.87±0.10,7年时为0.92±0.10;GH治疗效果P<0.005)。还观察到GH导致肩胛下皮褶厚度降低。通过生物电阻抗分析,GH治疗使全身水含量和去脂体重增加,体脂百分比降低。尽管所有组随时间均有变化,但未观察到GH治疗对葡萄糖耐量、胰岛素浓度、血脂水平、心脏大小、超声心动图舒张功能或运动耐量有显著的额外影响。总之,中年垂体功能减退成人长期进行GH替代治疗可使身体成分持续改善。与未接受GH治疗的垂体功能减退对照相比,7年时在血脂水平和运动耐量等其他益处并不明显。长期GH治疗未出现对葡萄糖耐量和胰岛素血症的潜在不利影响。